Thus, it is clear that a low-dose bortezomib treatment tested in this study can enhance anti-tumor CD8+ T cell function by promoting Notch-NFκB crosstalk, which has a potential to neutralize T cell immunosuppression by tumor. The gene discussed is CD8A; the disease is neoplasm.